The diabetes crisis in India is reaching a critical point, and the arrival of Ozempic, a global diabetes drug, has sparked both hope and controversy. But is it the miracle solution many are seeking? Novo Nordisk's MD, Vikrant Shrotriya, sheds light on this complex issue in an exclusive interview with NDTV.
The launch of Ozempic in India is a significant development, especially for the millions suffering from type 2 diabetes. While the drug has gained fame for its weight loss effects and celebrity endorsements, Novo Nordisk emphasizes that its focus in India is on diabetes treatment, backed by scientific evidence and responsible medical use.
But here's where it gets controversial...
The drug's potential to control blood sugar levels and support weight loss has led to a narrative that may be misleading. Shrotriya clarifies that while Ozempic can reduce HbA1c levels and aid in weight management, it is not a miracle cure. He warns against misinformation, which may discourage those who need the drug and encourage self-medication among others.
And this is the part most people miss: Ozempic is a powerful tool, but it's not a standalone solution. Shrotriya stresses the importance of medical supervision and dispels myths about the drug's side effects, stating that its benefits outweigh the risks when used correctly. He also highlights the company's commitment to patient education and responsible use, urging people to seek professional guidance rather than self-medicate.
As Novo Nordisk navigates the Indian market, they face questions about their stance on medication versus lifestyle changes. Shrotriya is clear: drugs are not a panacea. Diabetes, he explains, is a complex condition influenced by genetics, environment, and lifestyle. An integrated approach, including medication, diet, exercise, and monitoring, is essential.
A controversial interpretation: With the introduction of Ozempic and similar drugs, is the pharmaceutical industry shifting the focus from prevention to treatment? Shrotriya addresses this by emphasizing the importance of patient education and responsible medication use, ensuring the drug is not misused for cosmetic purposes.
When asked about competition from Eli Lilly's Mounjaro, Shrotriya takes a unique stance, stating that the real competition is the disease itself. With over 250 million Indians affected by obesity and diabetes, the focus should be on public health rather than market rivalry.
Ozempic's pricing strategy in India is tailored to ensure accessibility, with the company consulting various stakeholders. However, Shrotriya acknowledges that affordability is just one piece of the puzzle, as awareness and diagnosis remain challenges, particularly in non-urban areas.
In conclusion, Ozempic is a powerful addition to India's diabetes treatment arsenal, but it's not a magic bullet. It requires responsible use and should be part of a comprehensive approach to managing diabetes and obesity.
What are your thoughts on the introduction of Ozempic in India? Do you think it's a step towards a healthier future, or does it raise concerns about over-medication and misinformation? Share your opinions below, and let's continue the conversation!
